Multicentre General Practitioner Assessment of ‘Tenormin’ and Methyldopa

1979 ◽  
Vol 7 (4) ◽  
pp. 324-327
Author(s):  
J A Tweed ◽  
B Mason ◽  
R Sleigh
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
General Practitioner ◽  
Side Effects ◽  
Large Scale ◽  
Pressure Control ◽  
Hypertensive Patients ◽  
Relative Lack ◽  
Dosage Regime ◽  
Set Up

A large scale study in general practice was set up to investigate the effects, of transferring hypertensive patients from treatment with usually less than 1 g daily of methyldopa to atenolol ('Tenormin') 100 mg daily. The results demonstrate an improvement in blood pressure control with atenolol treatment and a reduction in the incidence of side-effects. The simple dosage regime, combined with proven effectiveness and a relative lack of side-effects makes atenolol a useful treatment for the hypertensive patient.

A Multicentre Study of a Once Daily Dosage of Acebutolol* in the Treatment of Hypertension in General Practice

1979 ◽  
Vol 7 (3) ◽  
pp. 201-214 ◽  
Author(s):  
P G Baker ◽  
J Goulton
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Adverse Reactions ◽  
Multicentre Trial ◽  
Pressure Control ◽  
Morning Dose ◽  
Progressive Reduction ◽  
Once Daily ◽  
Hypertensive Patients ◽  
Treatment Of Hypertension

A three-month open, multicentre trial was carried out in 2132 hypertensive patients under uncontrolled conditions in general practice, to assess the effectiveness and tolerance of acebutolol when given orally as a single morning dose, in the range of 200 to 1200 mg/day. Concomitant antihypertensive therapy was given to 702 patients. Forty-five patients, out of 1893 who were eligible for analysis, showed inadequate blood pressure control and were withdrawn from the study. There were 602 reports of side-effects or adverse reactions attributed to acebutolol in 584 patients, necessitating 120 withdrawals from the trial. The results showed that acebutolol given once daily produces a substantial and progressive reduction in blood pressure over the three months of the trial. The changes from pre-trial values of all haemodynamic assessments measured were statistically significant (p < 0-001).

Oxprenolol in Hypertension: A Report on 187 Patients in General Practice Originally Treated with Clonidine

1975 ◽  
Vol 3 (6) ◽  
pp. 395-398 ◽  
Author(s):  
W A Forrest
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Side Effects ◽  
Receptor Antagonist ◽  
Systolic Pressure ◽  
Hypertensive Patients ◽  
Β Receptor

Substitution, in part or totally, of the β- receptor antagonist, oxprenolol, for clonidine in 187 hypertensive patients resulted in significant reduction in blood pressure levels, particularly of systolic pressure. The incidence of unwanted side-effects was markedly reduced, with an accompanying improvement in the quality of the patient's life.

scholarly journals Multimorbidity and Blood Pressure Control in 37 651 Hypertensive Patients From Danish General Practice

2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Maja S. Paulsen ◽  
Morten Andersen ◽  
Janus L. Thomsen ◽  
Henrik Schroll ◽  
Pia V. Larsen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Hypertensive Patients

A Multicentre Study Examining the Substitution of Trasidrex for the Free Combination of Slow-Trasicor and Navidrex-K

1979 ◽  
Vol 7 (6) ◽  
pp. 524-527 ◽  
Author(s):  
A F Ebbutt ◽  
R W Elsdon Dew
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
General Practice ◽  
Essential Hypertension ◽  
Side Effects ◽  
Open Study ◽  
Global Assessment ◽  
Pressure Control ◽  
Time Intervals ◽  
The Mean

A multicentre, open study of general practice patients with essential hypertension who were currently being treated with oxprenolol and cyclopenthiazide was undertaken in which the patients were transferred to Trasidrex for 12 weeks. Weight, blood pressure, heart rate and side-effects were assessed pre-trial and at 4-week intervals. A global assessment was also made at the same time intervals. The mean serum potassium remained virtually unchanged after 12 weeks treatment with Trasidrex. Blood pressure control was marginally improved during the study and it is thought possible that better patient compliance might explain this. Trasidrex was tolerated equally as well as the free combination.

Blood Pressure Control and Associated Factors Among Hypertensive Patients Attending Shashemene Referral Hospital, Oromia, Ethiopia

2021 ◽  
pp. 001857872110613
Author(s):  
Aliyi Anota ◽  
Teshome Nedi
Keyword(s):  
Blood Pressure ◽  
Side Effects ◽  
Blood Pressure Control ◽  
Associated Factors ◽  
Antihypertensive Drugs ◽  
Pressure Control ◽  
Referral Hospital ◽  
Hypertensive Patients ◽  
The Mean ◽  
Study Participants

Background: Hypertension is public health challenge worldwide. It is defined as persistently elevated arterial blood pressure (BP), systolic BP (SBP) ≥140 mmHg and/or diastolic BP (DBP) ≥90 mmHg or use of antihypertensive medication in adults older than 18 years. The aim of this study was to assess blood pressure control and associated factors among hypertensive patients attending the outpatient department of Shashemene Referral Hospital. Methods: Hospital based cross sectional study was conducted to determine level of blood pressure control and associated factors among hypertensive patients on medical follow-up. A medical chart review and interview was conducted from July 1 to October 31 2018. Result: A total of 325 participants were included in this study with response rate of 320 (98.5%). More than half of study participants were males 171 (53.4%). The mean age of the respondents was 55.10 (SD ± 12.7) years and majority of the respondents 191 (59.7%) were within age of less than 60 years old. The mean Systolic blood pressure (SBP) was 131.80 mmHg (SD ± 20.92) while the mean diastolic blood pressure (DBP) was 82.30 mmHg (SD ± 10.52). About 51.30% of study participants had a controlled SBP and 54.7% had a controlled DBP. The overall control of BP was achieved in 40.3% of the study participants. Multivariable logistic regression analysis showed that age, experience of side effects, frequency of BP measuring, number of antihypertensive drugs used, duration on antihypertensive, source of medication and physical exercise showed significant association with blood pressure control. Conclusion: Blood pressure control level among chronic hypertensive patients at outpatient department was low. Age of patients, educational level, experience of side effects, and number of antihypertensive drugs used were important determinant factors associated with blood pressure control among study participants.

Trasidrex (A Fixed Combination of Slow Trasicor 160mg and Navidrex 0.25mg) in the Treatment of Hypertension: A Multicentre Clinical Trial in General Practice

1978 ◽  
Vol 6 (6) ◽  
pp. 494-498 ◽  
Author(s):  
A F Ebbutt ◽  
R W Elsdon-Dew ◽  
J E Murphy
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
Blood Pressure Control ◽  
Fixed Combination ◽  
Pressure Control ◽  
Combination Tablet ◽  
Multicentre Clinical Trial ◽  
Treatment Of Hypertension

Sixty-two patients with hypertension who were treated with a free combination of Slow Trasicor or Trasicor and Navidrex K were transferred to a fixed combination tablet, Trasidrex (slow oxprenolol 160 mg + cyclopenthiazide 0.25 mg). Blood pressure control was marginally improved and there was no increase in side-effects.

A Study of Once Daily Tenormin (Atenolol) in Hypertension: Some Implications in Patient Compliance

1976 ◽  
Vol 4 (5) ◽  
pp. 347-351 ◽  
Author(s):  
A M Harris ◽  
K V Woollard ◽  
J A Tweed
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Clinical Study ◽  
Side Effects ◽  
Patient Compliance ◽  
Pressure Control ◽  
Once Daily ◽  
Hypertensive Patients ◽  
Significant Difference ◽  
Pre Treatment

A clinical study is described in which hypertensive patients on no drug therapy were given atenolol in increasing doses from 50 mg twice daily to 200 mg twice daily until the diastolic blood pressure was 90 mm Hg or below. At this stage the drug was withdrawn until blood pressure readings had risen to pre-treatment levels. The same dose of atenolol was then re-introduced but now given once-a-day (in the morning) and was continued for four weeks. Of the eleven patients entering the study, one withdrew as his blood pressure was not controlled on a dose of 200 mg of atenolol twice daily, and another because on withdrawal of atenolol his blood pressure did not rise to pre-treatment levels. The remaining nine patients completed the study. There was a statistically significant fall in blood pressure on both atenolol regimes and there was no significant difference between the blood pressure control achieved on twice-a-day and once-a-day administration. Only one patient developed side-effects; this being an asthmatic who developed mild dyspnoea on atenolol which did not necessitate withdrawal of the drug. It is concluded that once-a-day administration of a given dose of atenolol is therapeutically equivalent to twice-a-day administration. The implications of this in terms of better patient compliance, and thus better prognosis, are discussed.

Sign in / Sign up

Export Citation Format

Share Document